MMP2 and osteosarcoma: Taken together, our in vivo findings suggest that administration of TGZ not only decreases the expression of MMP-2 and invasiveness, but also decreases the expression of VEGF and local vessel formation, thus preventing both the growth of primary osteosarcoma and the development of metastasis in the lung.